GSK, Vir Biotech File For Emergency Use Nod For Intramuscular Sotrovimab For COVID-19

GlaxoSmithKline plc GSK and Vir Biotechnology Inc VIR have applied to the FDA to include intramuscular (IM) administration to sotrovimab's Emergency Use Authorization (EUA) for COVID-19.

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsHealth CareFDAMoversTrading IdeasGeneralBriefsCOVID-19 Coronavirus
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!